GRAIL Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 700


  • Latest Deal Type
  • M&A
  • (Announced)

  • Investors
  • 1

GRAIL General Information

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Clinics/Outpatient Services
Diagnostic Equipment
Parent Company
Corporate Office
  • 1525 O'Brien Drive
  • Menlo Park, CA 94025
  • United States
+1 (833) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GRAIL Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 11-Dec-2023 Announced Generating Revenue
5. Merger/Acquisition 18-Aug-2021 00.00 000 00.00 Completed Generating Revenue
4. Later Stage VC (Series D) 06-May-2020 00000 000 00.000 Completed Generating Revenue
3. Later Stage VC (Series C) 21-May-2018 00000 00.000 00.00 Completed Generating Revenue
2. Early Stage VC (Series B) 22-Nov-2017 $1.21B $1.31B 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-2016 $100M $100M 00000 Completed Startup
To view GRAIL’s complete valuation and funding history, request access »

GRAIL Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 0.00
Series B 309,256,591 $0.001000 $4.01 $4.01 1x $4.01 41.14%
Series A 85,000,000 $0.001000 $1 $1 1x $1 11.31%
To view GRAIL’s complete cap table history, request access »

GRAIL Comparisons

HQ Location
Total Raised
Post Valuation
Menlo Park, CA
700 As of 2022


aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volu
Waltham, MA
00 As of 0000
00000 0000-00-00
000000&0 00000


dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exe
0000000000 000000000
Seattle, WA
00 As of 0000
00000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GRAIL Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exosome Diagnostics Formerly VC-backed Waltham, MA 00 00000 000000&0 00000
RareCyte Venture Capital-Backed Seattle, WA 00 00000 00000000000 00000
Epic Sciences Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
Genomic Expression Venture Capital-Backed Beverly, MA 00 00.00 00000 00000
CellMax Life Venture Capital-Backed Sunnyvale, CA 00 000.00 000000 0 000.00
You’re viewing 5 of 27 competitors. Get the full list »

GRAIL Patents

GRAIL Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240136018-A1 Component mixture model for tissue identification in dna samples Pending 19-Oct-2022 000000000
US-20240127955-A1 System and methods for mapping cancer classifications Pending 17-Oct-2022 000000000
US-20240117435-A1 Systems and methods for performing methylation-based risk stratification for myelodysplastic syndromes Pending 05-Oct-2022 0000000000
US-20240038335-A1 Systems and methods for detecting disease subtypes Pending 01-Aug-2022 000000000
US-20240055073-A1 Sample contamination detection of contaminated fragments with cpg-snp contamination markers Pending 25-Jul-2022 G16B20/20
To view GRAIL’s complete patent history, request access »

GRAIL Executive Team (31)

Name Title Board Seat Contact Info
Joshua Ofman MD President
Aaron Freidin Chief Financial Officer
Julie Currie Chief People Officer
Amoolya Singh Ph.D Senior Vice President of Research & Chief Scientific Officer
Daryl Gottlieb Director, ASO Partnerships
You’re viewing 5 of 31 executive team members. Get the full list »

GRAIL Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GRAIL Former Investors (43)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Ally Bridge Group PE/Buyout Minority 000 0000 000000 0 Corporation Minority 000 0000 000000 0
Amino Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 43 investors. Get the full list »

GRAIL Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Today (Entertainment Software) 05-Apr-2024 0000 00000 000 Entertainment Software
MetalCore 12-Mar-2024 00000 0000 000 Entertainment Software
Cirina 31-May-2017 Merger/Acquisition Biotechnology 0000000 0
To view GRAIL’s complete investments and acquisitions history, request access »


  • When was GRAIL founded?

    GRAIL was founded in 2015.

  • Who is the founder of GRAIL?

    Alexander Aravanis Ph.D, Jeffrey Huber, and Mostafa Ronaghi Ph.D are the founders of GRAIL.

  • Who is the CEO of GRAIL?

    Robert Ragusa is the CEO of GRAIL.

  • Where is GRAIL headquartered?

    GRAIL is headquartered in Menlo Park, CA.

  • What is the size of GRAIL?

    GRAIL has 700 total employees.

  • What industry is GRAIL in?

    GRAIL’s primary industry is Biotechnology.

  • Is GRAIL a private or public company?

    GRAIL is a Private company.

  • What is GRAIL’s current revenue?

    The current revenue for GRAIL is 00000.

  • How much funding has GRAIL raised over time?

    GRAIL has raised $2B.

  • Who are GRAIL’s investors?

    6 Dimensions Capital, ARCH Venture Partners, Ally Bridge Group,, and Amino Capital are 5 of 43 investors who have invested in GRAIL.

  • Who are GRAIL’s competitors?

    Exosome Diagnostics, RareCyte, Epic Sciences, Genomic Expression, and CellMax Life are some of the 27 competitors of GRAIL.

  • When was GRAIL acquired?

    GRAIL was acquired on 11-Dec-2023.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »